Ibrutinib + Venetoclax in Untreated WM
Clinical trial NCT04273139 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04273139
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-09
- Primary completion
- 2022-06-06
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.